FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891287621> ?p ?o ?g. }

• W2891287621 endingPage "9526" @default.
• W2891287621 startingPage "9526" @default.
• W2891287621 abstract "9526 Background: Prior analyses of phase 2 (BREAK-2; NCT01153763) and phase 3 (BREAK-3; NCT01227889) trials showed that durable clinical benefit and tolerability lasting ≥ 3 y are achievable with the BRAF inhibitor dabrafenib in some patients (pts) with BRAFV600–mutant metastatic melanoma. Here, we report 5-y landmark analyses for BREAK-2 and BREAK-3. Methods: BREAK-2, a single-arm, phase 2 study, evaluated dabrafenib 150 mg twice daily in pts with stage IV BRAF V600E/K–mutant MM. BREAK-3, an open-label, randomized (3:1), phase 3 study, assessed dabrafenib 150 mg twice daily vs dacarbazine 1000 mg/m 2 every 3 weeks in pts with previously untreated BRAFV600E–mutant unresectable stage III or stage IV MM. Updated analyses were performed to describe ≥ 5-y outcomes in each study. Results: BREAK-2 enrolled 92 pts (V600E, n = 76; V600K, n = 16), of whom most (90%) had prior systemic anticancer therapy. At data cutoff (17 Jun 2016), all pts had discontinued, mostly due to progression (84%). In V600E pts, 5-y progression-free survival (PFS) was 11%, and 5-y overall survival (OS) was 20%. Postprogression immunotherapy was received by 22% of enrolled pts. In BREAK-3 (data cutoff, 16 Sep 2016), median follow-up was 18.6 mo for the dabrafenib arm (n = 187) and 12.8 mo for the dacarbazine arm (n = 63). Follow-up for the 37 dacarbazine-arm pts (59%) who crossed over to receive dabrafenib was based on the initial assignment of dacarbazine. The 5-y PFS was 12% vs 3% and 5-y OS was 24% vs 22% for the dabrafenib and dacarbazine arms, respectively. A subset of pts in each respective arm received postprogression anti–CTLA-4 (24% vs 24%) and/or anti–PD-1 (8% vs 2%) therapy, whereas 31% vs 17% did not receive any further therapy following study treatment. No new safety signals were observed in either study with long-term follow-up. Additional characterization of pts using cfDNA analysis will be presented. Conclusions: These data provide the longest reported PFS and OS follow-up for BRAF inhibitor monotherapy in BRAF V600–mutant MM. Both BREAK-2 and BREAK-3 showed that 11%-12% of pts initially treated with single-agent dabrafenib remained progression free at 5 y. Clinical trial information: NCT01153763; NCT01227889." @default.
• W2891287621 created "2018-09-27" @default.
• W2891287621 creator A5009857756 @default.
• W2891287621 creator A5011257308 @default.
• W2891287621 creator A5012502212 @default.
• W2891287621 creator A5015081105 @default.
• W2891287621 creator A5016161312 @default.
• W2891287621 creator A5025478490 @default.
• W2891287621 creator A5029398339 @default.
• W2891287621 creator A5034365278 @default.
• W2891287621 creator A5041036069 @default.
• W2891287621 creator A5042973046 @default.
• W2891287621 creator A5044736874 @default.
• W2891287621 creator A5055627811 @default.
• W2891287621 creator A5068309846 @default.
• W2891287621 creator A5079833339 @default.
• W2891287621 creator A5083745558 @default.
• W2891287621 creator A5083883593 @default.
• W2891287621 creator A5084791255 @default.
• W2891287621 creator A5087671839 @default.
• W2891287621 creator A5088390068 @default.
• W2891287621 date "2017-05-20" @default.
• W2891287621 modified "2023-10-17" @default.
• W2891287621 title "Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma." @default.
• W2891287621 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.9526" @default.
• W2891287621 hasPublicationYear "2017" @default.
• W2891287621 type Work @default.
• W2891287621 sameAs 2891287621 @default.
• W2891287621 citedByCount "5" @default.
• W2891287621 countsByYear W28912876212018 @default.
• W2891287621 countsByYear W28912876212019 @default.
• W2891287621 countsByYear W28912876212020 @default.
• W2891287621 crossrefType "journal-article" @default.
• W2891287621 hasAuthorship W2891287621A5009857756 @default.
• W2891287621 hasAuthorship W2891287621A5011257308 @default.
• W2891287621 hasAuthorship W2891287621A5012502212 @default.
• W2891287621 hasAuthorship W2891287621A5015081105 @default.
• W2891287621 hasAuthorship W2891287621A5016161312 @default.
• W2891287621 hasAuthorship W2891287621A5025478490 @default.
• W2891287621 hasAuthorship W2891287621A5029398339 @default.
• W2891287621 hasAuthorship W2891287621A5034365278 @default.
• W2891287621 hasAuthorship W2891287621A5041036069 @default.
• W2891287621 hasAuthorship W2891287621A5042973046 @default.
• W2891287621 hasAuthorship W2891287621A5044736874 @default.
• W2891287621 hasAuthorship W2891287621A5055627811 @default.
• W2891287621 hasAuthorship W2891287621A5068309846 @default.
• W2891287621 hasAuthorship W2891287621A5079833339 @default.
• W2891287621 hasAuthorship W2891287621A5083745558 @default.
• W2891287621 hasAuthorship W2891287621A5083883593 @default.
• W2891287621 hasAuthorship W2891287621A5084791255 @default.
• W2891287621 hasAuthorship W2891287621A5087671839 @default.
• W2891287621 hasAuthorship W2891287621A5088390068 @default.
• W2891287621 hasConcept C126322002 @default.
• W2891287621 hasConcept C143998085 @default.
• W2891287621 hasConcept C184235292 @default.
• W2891287621 hasConcept C197934379 @default.
• W2891287621 hasConcept C2776131300 @default.
• W2891287621 hasConcept C2776694085 @default.
• W2891287621 hasConcept C2777658100 @default.
• W2891287621 hasConcept C2778375690 @default.
• W2891287621 hasConcept C2778472372 @default.
• W2891287621 hasConcept C2778830669 @default.
• W2891287621 hasConcept C2780739268 @default.
• W2891287621 hasConcept C2780964509 @default.
• W2891287621 hasConcept C2994587330 @default.
• W2891287621 hasConcept C31760486 @default.
• W2891287621 hasConcept C502942594 @default.
• W2891287621 hasConcept C535046627 @default.
• W2891287621 hasConcept C57074206 @default.
• W2891287621 hasConcept C71924100 @default.
• W2891287621 hasConcept C86803240 @default.
• W2891287621 hasConcept C95444343 @default.
• W2891287621 hasConceptScore W2891287621C126322002 @default.
• W2891287621 hasConceptScore W2891287621C143998085 @default.
• W2891287621 hasConceptScore W2891287621C184235292 @default.
• W2891287621 hasConceptScore W2891287621C197934379 @default.
• W2891287621 hasConceptScore W2891287621C2776131300 @default.
• W2891287621 hasConceptScore W2891287621C2776694085 @default.
• W2891287621 hasConceptScore W2891287621C2777658100 @default.
• W2891287621 hasConceptScore W2891287621C2778375690 @default.
• W2891287621 hasConceptScore W2891287621C2778472372 @default.
• W2891287621 hasConceptScore W2891287621C2778830669 @default.
• W2891287621 hasConceptScore W2891287621C2780739268 @default.
• W2891287621 hasConceptScore W2891287621C2780964509 @default.
• W2891287621 hasConceptScore W2891287621C2994587330 @default.
• W2891287621 hasConceptScore W2891287621C31760486 @default.
• W2891287621 hasConceptScore W2891287621C502942594 @default.
• W2891287621 hasConceptScore W2891287621C535046627 @default.
• W2891287621 hasConceptScore W2891287621C57074206 @default.
• W2891287621 hasConceptScore W2891287621C71924100 @default.
• W2891287621 hasConceptScore W2891287621C86803240 @default.
• W2891287621 hasConceptScore W2891287621C95444343 @default.
• W2891287621 hasIssue "15_suppl" @default.
• W2891287621 hasLocation W28912876211 @default.
• W2891287621 hasOpenAccess W2891287621 @default.
• W2891287621 hasPrimaryLocation W28912876211 @default.
• W2891287621 hasRelatedWork W109521097 @default.
• W2891287621 hasRelatedWork W1996920559 @default.

• next